Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833469 · ClinicalTrials.gov registry record · Phase 4
Escitalopram (Lexapro) for the Treatment of Postpartum Depression
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT00833469: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00833469 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00833469, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether women with postpartum major depressive disorder (MDD) will experience a significant decrease in depressive symptoms from baseline over an eight-week treatment intervention with escitalopram (Lexapro). Also, to determine whether women with postpartum MDD will experience a significant decrease in anxiety symptoms.
Interventions
- DRUG Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00833469
The ClinicalTrials.gov registry entry for NCT00833469 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Escitalopram is the first listed.
NCT00833469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00833469 about?
NCT00833469 is a clinical study titled "Escitalopram (Lexapro) for the Treatment of Postpartum Depression". The purpose of this study is to determine whether women with postpartum major depressive disorder (MDD) will experience a significant decrease in depressive symptoms from baseline over an eight-week treatment intervention with escitalopram (Lexapro). Also, to determine whether women with postpartum ...
What is the current status of trial NCT00833469?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2009-01. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00833469?
The interventions under investigation include: Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00833469?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.